TEVA - Teva Pharmaceutical Industries Limited
| Previous Close | 21.43 |
| Open | 21.51 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 1000 |
| Day's Range | 21.20 - 21.61 |
| 52 Week Range | 10.85 - 25.96 |
| Volume | 8,304,949 |
| Avg. Volume | 12,051,584 |
| Market Cap | 21.618B |
| Beta (3Y Monthly) | 0.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -10.09 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2017-11-27 |
| 1y Target Est | 21.53 |
- CNBC Videos•6 days ago
Stephanie Link's big buy in final trades
Tech, healthcare and a whale - should you own these stocks?
- Market Realist•9 hours ago
How Novartis’s Innovative Medicines Business Performed in Q3
Novartis’s (NVS) Innovative Medicines business includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology. The Innovative Medicines business contributed over 67.2% of the total revenues for Novartis and saw 6% growth in year-over-year (or YoY) revenues to ~$8.6 billion during the third quarter of 2018.
- Market Realist•12 hours ago
Pfizer’s Third-Quarter Earnings: Analysts’ Estimates
Pfizer (PFE), one of the leading pharmaceutical companies, is scheduled to release its third-quarter earnings on October 30. For the third quarter, analysts expect Pfizer to report an EPS of $0.75 on revenues of $13.5 billion.
- American City Business Journals•14 hours ago
Teva's move of N. American HQ from Montco to N.J. takes another step forward
N.J. provided Teva with a $40M incentive package to lure the company's consolidated North American headquarters away from North Wales, Pa.
- Reuters•17 hours ago
BRIEF-Harbin Pharmaceutical Signs Agreement With Israel's Teva Pharmaceutical Industries
(Refiles with correct link) Oct 22 (Reuters) - Harbin Pharmaceutical Group Co Ltd : * SAYS IT SIGNS AUTHORIZATION AND DISTRIBUTION AGREEMENT WITH ISRAEL'S TEVA PHARMACEUTICAL INDUSTRIES, EXPECTS INVESTMENT ...
- Business Wire•2 days ago
Teva and New Jersey Governor Murphy Formalize North America Headquarters Move with Ceremony in Israel
Teva Pharmaceuticals announced that Teva executives Kåre Schultz and Brendan O’Grady, alongside State of New Jersey Governor, Phil Murphy, formalized Teva’s commitment to consolidate its North America Commercial business areas into New Jersey (NJ) today at the company’s global headquarters in Petach Tikva, Israel. Announced earlier this year as part of a global restructuring process, Teva will establish its North America headquarters in Parsippany-Troy Hills, including more than 1,000 high-wage jobs and the transfer and creation of more than 800 positions.
- Zacks•3 days ago
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $21.45 in the latest trading session, marking a +0.85% move from the prior day.
Market Realist•3 days agoA Performance Overview of JNJ’s Beauty and OTC Businesses
Johnson & Johnson’s (JNJ) beauty business generated revenue of $1.1 billion in the third quarter compared to $1.0 billion in the third quarter of 2017, reflecting a ~4.4% YoY rise.
- GlobeNewswire•4 days ago
New Research: Key Drivers of Growth for Teva Pharmaceutical Industries, Axovant Sciences, SolarEdge Technologies, NantHealth, Kosmos Energy, and Retrophin — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Market Realist•4 days ago
What Are Pfizer’s Revenue Drivers?
Pfizer (PFE) reported revenues of $13.5 billion during the second quarter—4% revenue growth YoY compared to $12.9 million during the second quarter of 2017. The revenues are expected to increase 2.8% to $13.5 billion during the third quarter.
- Reuters•5 days ago
Exclusive: Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva
Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers. The decision represents a setback for Israel-based Teva , which is in the midst of a corporate restructuring and had hoped to capture a sizable share of the multibillion-dollar migraine market. Express Scripts is also taking steps to limit use of the Amgen and Lilly migraine drugs to patients it says are most likely to benefit from them.
Reuters•5 days agoExpress Scripts covers Amgen, Lilly migraine drugs, excludes Teva
Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers. The decision represents a setback for Israel-based Teva , which is in the midst of a corporate restructuring and had hoped to capture a sizable share of the multibillion-dollar migraine market. Express Scripts is also taking steps to limit use of the Amgen and Lilly migraine drugs to patients it says are most likely to benefit from them.
- Investing.com•6 days ago
Stocks - Netflix Soars in Pre-market; IBM, Tilray, Canopy Growth Sink; Tesla Rises
Investing.com - Stocks in focus in pre-market trade Wednesday:
- Zacks•6 days ago
Regeneron's Dupixent Meets Goals in Nasal Polyps Studies
Regeneron's (REGN) atopic dermatitis drug, Dupixent meets goals in two late-stage studies for nasal polyps.
- CNBC•6 days ago
Stocks making the biggest move premarket: NFLX, IBM, CSX, UAL, TEVA & more
Check out the companies making headlines before the bell: Netflix NFLX – Netflix reported quarterly profit of 89 cents per share , easily beating the consensus estimate of 68 cents a share. Revenue was in line with Street forecasts, and the important metric of net subscriber additions was well above analysts' expectations for the video streaming service.
Market Realist•10 days agoA Financial Overview of Bausch Health in October
Bausch Health’s (BHC) net revenues declined from $4.3 billion in the first half of 2017 to $4.1 billion in the first half of this year, reflecting an ~5.0% YoY (year-over-year) decline. In the second quarter, Bausch Health generated net revenues of $2.1 billion compared to $2.2 billion in the second quarter of 2017.
Market Realist•10 days agoHow Analysts View Bausch Health in October
In the second quarter, Bausch Health (BHC) reported net income and diluted EPS of -$873.0 million and -$2.49, respectively, compared to -$38.0 million and -$0.11 in the second quarter of 2017. In the first half, Bausch Health generated net income and diluted EPS of -$3.45 million and -$9.84, respectively, compared to $590.0 million and $1.68 in the first half of 2017.
- Reuters•11 days ago
U.S. appeals court upholds ruling that canceled Teva Copaxone patents
A U.S. appeals court on Friday upheld a ruling that canceled patents owned by Teva Pharmaceutical Industries Ltd on its blockbuster multiple sclerosis drug Copaxone. The ruling was a victory for a group of generic drug companies, including Mylan NV and Novartis AG unit Sandoz, that challenged the validity of Teva's patents in order to sell generic versions. Teva did not immediately respond to requests for comment.
Market Realist•11 days agoInvestor Insights: Teva Pharmaceutical’s Valuation Multiples
On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x. Its forward EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) multiple, a capital-structure-neutral valuation measure, is 10.4x, which is higher than the industry average of 9.4x. A company’s forward PE ratio reflects the market’s views in regards to the company’s growth potential over the next 12 months.
Market Realist•11 days agoAnalysts Raised Their Recommendations on Teva Stock in October
Leerink raised its recommendation on Teva Pharmaceutical Industries from “underperform” to “market perform.” The firm also raised its target price from $16 to $24 on October 1. The stock registered a rise of ~3.6% during premarket trading on the day. Teva has strong fundamentals that have been improving recently due in part to the more stable generics pricing environment in the United States.
Market Realist•11 days agoWall Street Analysts See Upside Potential of 3.9% in TEVA
Teva Pharmaceutical Industries (TEVA) is gradually recovering from the lows it witnessed in late 2017 due to generics competition, pricing pressure, and declining Copaxone sales. Teva’s growth prospects have been boosted by the FDA’s recent approval of its migraine drug. In recent months, analysts have been more confident about the company’s growth prospects. As of October 11, 24 analysts covered Teva stock and were included in a recent Reuters survey.
- Zacks•12 days ago
Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing
Teva (TEVA) and partner Celltrion gets unanimous vote from an FDA advisory committee recommending approval of CT-P10, their proposed biosimilar to Roche's Rituxan.
- Business Wire•12 days ago
Teva Draws on Patient Experience to Empower Those Living with Chronic Conditions
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the European launch of Life Effects, a patient-centric website hosting content created by patients and checked by experts, at the European Committee for the Treatment and Research of Multiple Sclerosis (ECTRIMS) Congress in Berlin. With content developed in collaboration with patients, Life Effects consists of articles, videos and podcasts that offer information, insight and inspiration to people suffering from one or more chronic condition, including MS, particularly focusing on the impact a condition has on a patient’s day-to-day life. By working with a core group of patients on an ongoing basis, who make direct contributions which are reviewed by experts, Life Effects offers a first-hand, credible perspective on what it’s like to live with a chronic condition.
- Kiplinger•12 days ago
5 “Warren Buffett Stocks” That Might Not Be His Ideas
Warren Buffett is one of the most successful investors (if not the most) of all time, and chief stock-picker for Berkshire Hathaway (BRK.B). Since assembling the group of companies that would eventually become Berkshire back in 1964, the so-called Oracle of Omaha's baby has trounced the broad market's return. That has led the market to hunt down so-called "Warren Buffett stocks" in hopes of benefitting from his wisdom and discipline. But Buffett, at 88 years of age, already has had to step away from complete control of Berkshire Hathaway, unable to keep up the pace of study needed to keep his fund's holdings optimized. Other acolytes have emerged, and out of necessity have started making stock picks for Berkshire without necessarily requiring Buffett's blessing. Todd Combs and Ted Weschler are at least running a big part of the show. Their selections aren't always divulged as non-Buffett picks. From a shareholder's perspective, Berkshire and its collective chiefs are one and the same, and reported as such. It's sometimes quite clear, though, that Warren Buffett had little-to-nothing to do with a particular holding. Here are five Berkshire Hathaway holdings that might not necessarily be "Warren Buffett stocks." That's because they're out of character with the decades' worth of insight and tips he's been willing to dish out. More importantly: They might give us clues as to the direction of Berkshire's picks once Buffett is completely out of the picture. SEE ALSO: How Well Do You Really Know Warren Buffett?
- Business Wire•13 days ago
Celltrion and Teva Announce FDA Oncologic Drugs Advisory Committee Recommends Approval of Celltrion BLA for CT-P10, a Proposed Rituximab Biosimilar
Celltrion, Inc. (068270.KS) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee voted unanimously 16-0 to recommend approval of CT-P10, a proposed monoclonal antibody (mAb) biosimilar to Rituxan®1 (rituximab) for the treatment of adult patients in three proposed indications.
